trovan

Description

Trovan (trovafloxacin mesylate) is a synthetic fluoroquinolone antibiotic that was developed by Pfizer. It was marketed for the treatment of bacterial infections, including pneumonia, skin infections, and urinary tract infections. However, it was withdrawn from the market in 1998 after concerns about its safety, including reports of liver damage and fatal adverse effects, particularly in children. Trovan's synthesis involves a multi-step process that starts with a substituted aniline derivative and proceeds through a series of reactions, including cyclization and oxidation. The drug exerts its antibacterial effect by inhibiting DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and repair. Due to its potent activity against a wide range of bacteria, Trovan was initially considered a promising antibiotic. However, its association with serious adverse events led to its withdrawal and fueled debates about the ethical conduct of clinical trials in developing countries. The case of Trovan remains a significant example of the complexities surrounding drug development, safety, and ethical considerations.'

trovafloxacin mesylate : A methanesulfonate (mesylate) salt prepared from equimolar amounts of trovafloxacin and methanesulfonic acid. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]